Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
1.450
-0.010 (-0.68%)
Aug 14, 2025, 11:32 AM - Market open
Company Description
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases.
Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders.
The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018.
The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Camp4 Therapeutics Corporation
| Country | United States |
| Founded | 2016 |
| IPO Date | Oct 11, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Joshua Mandel-Brehm |
Contact Details
Address: One Kendall Square, 3rd Floor Cambridge, Massachusetts 02139 United States | |
| Phone | 617-651-8867 |
| Website | camp4tx.com |
Stock Details
| Ticker Symbol | CAMP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $11.00 |
| CIK Code | 0001736730 |
| CUSIP Number | 13463J101 |
| ISIN Number | US13463J1016 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joshua Mandel-Brehm | Chief Executive Officer, President and Director |
| Dr. Richard A. Young Ph.D. | Founder and Independent Director |
| Kelly Gold | Chief Financial Officer |
| Dr. Yuri Maricich M.B.A., M.D. | Chief Medical Officer |
| Dr. Leonard I. Zon M.D. | Founder and Chairman of Scientific Advisory Board |
| Caleb Moore | Chief Business Operations Officer |
| Dr. David Bumcrot Ph.D. | Chief Scientific Officer and Senior Vice President of Research |
| Michelle Gates | Senior Vice President and Chief People Officer |
| Dr. Satya Kuchimanchi Ph.D. | Senior Vice President of Technical Operations |
| Dr. Daniel Tardiff Ph.D. | Senior Vice President and Head of Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 13, 2025 | 8-K | Current Report |
| May 16, 2025 | 8-K | Current Report |
| May 14, 2025 | SCHEDULE 13G | Filing |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| Apr 30, 2025 | ARS | Filing |
| Apr 30, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 27, 2025 | 10-K | Annual Report |